Table 2 Characteristics of subgroups based on the quartile of hs-CRP
Variable | total (n = 544) | quartile 1 (n = 136) | quartile 2 (n = 136) | quartile 3 (n = 136) | quartile 4 (n = 136) | P |
|---|---|---|---|---|---|---|
Demographic characteristics | ||||||
Age, years | 65.4 ± 11.8 | 65.0 ± 10.3 | 65.8 ± 12.0 | 63.8 ± 11.6 | 66.9 ± 13.0 | 0.169 |
Male, % | 387 (71.1) | 94(69.1) | 103(75.7) | 88(64.7) | 102(75.0) | 0.145 |
Vascular risk factors, % | ||||||
Hypertension | 360 (66.2) | 93 (68.4) | 90 (66.2) | 91 (66.9) | 86 (63.2) | 0.836 |
Diabetes mellitus | 161 (29.6) | 36 (26.5) | 36 (26.5) | 40 (29.4) | 49 (36.0) | 0.243 |
Dyslipidemia | 91 (16.7) | 25 (18.4) | 21 (15.4) | 22 (16.2) | 23 (16.9) | 0.927 |
Current smoking | 221 (40.6) | 55 (40.4) | 63 (46.3) | 47 (34.6) | 56 (41.2) | 0.270 |
Current drinking | 162(29.8) | 47 (34.6) | 44 (32.6) | 33 (24.3) | 38 (27.9) | 0.545 |
Previous stroke | 67 (12.3) | 18 (13.2) | 16 (11.8) | 22 (16.2) | 11 (8.1) | 0.234 |
Peripheral artery disease | 16 (2.9) | 3 (2.2) | 3 (2.2) | 4 (2.9) | 6 (4.4) | 0.672 |
Coronary artery disease | 66 (12.1) | 18 (13.2) | 19 (14.0) | 15 (11.0) | 14 (10.3) | 0.760 |
Clinical data | ||||||
Previous antiplatelet, % | 57 (10.5) | 13 (9.6) | 14 (10.3) | 17 (12.5) | 13 (9.6) | 0.839 |
Previous statin, % | 16 (2.9) | 5 (3.7) | 4 (2.9) | 5 (3.7) | 2 (1.5) | 0.627 |
SBP, mmHg | 144.6 ± 20.6 | 145.0 ± 19.0 | 143.1 ± 21.3 | 143.6 ± 20.5 | 146.8 ± 21.7 | 0.465 |
DBP, mmHg | 85.8 ± 12.3 | 85.5 ± 12.3 | 84.5 ± 12.5 | 86.6 ± 11.8 | 86.5 ± 12.7 | 0.478 |
Body mass index, kg/m2 | 24.5 ± 3.5 | 24.1 ± 3.7 | 24.1 ± 3.0 | 24.9 ± 3.2 | 24.8 ± 3.9 | 0.145 |
Initial totaol NIHSS, score | 2 (2–4) | 2 (1–4) | 2 (2–4) | 2 (1–4) | 3 (2–4) | 0.631 |
White matter lesions, % | 354 (65.1) | 94 (69.1) | 85 (62.5) | 88 (64.7) | 87 (64.0) | 0.692 |
Intravenous thrombolysis, % | 91 (16.7) | 19 (14.0) | 22 (16.2) | 24 (17.6) | 26 (19.1) | 0.703 |
PMD, % | 85 (15.6) | 7 (5.1) | 3 (2.2) | 30 (22.1) | 45 (33.1) | < 0.001 |
MCA stenosis, % | ||||||
0 | 307 (56.4) | 83 (61.0) | 74 (54.4) | 73 (53.7) | 77 (56.6) | 0.611 |
≤ 50% | 208 (38.2) | 48 (35.3) | 54 (39.7) | 54 (39.7) | 52 (38.2) | 0.862 |
>50% | 29 (5.3) | 5 (3.7) | 8 (5.9) | 9 (6.6) | 7 (5.1) | 0.735 |
VBA stenosis, % | ||||||
0 | 302 (55.5) | 80 (58.8) | 71 (52.2) | 73 (53.7) | 78 (57.4) | 0.664 |
≤ 50% | 203 (37.3) | 48 (35.3) | 56 (41.2) | 51 (37.5) | 48 (35.3) | 0.719 |
>50% | 39 (7.2) | 8 (5.9) | 9 (6.6) | 12 (8.8) | 10 (7.4) | 0.809 |
Carotid artery atheromatosis, % | ||||||
Absence | 222 (40.8) | 46 (33.8) | 59 (43.4) | 62 (45.6) | 55 (40.4) | 0.220 |
Moderate | 278 (51.1) | 76 (55.9) | 69 (50.7) | 62 (45.6) | 71 (52.2) | 0.369 |
Significant | 44 (8.1) | 14 (10.3) | 8 (5.9) | 12 (8.8) | 10 (7.4) | 0.577 |
Silent lacunar infarcts, % | 246 (45.2) | 63 (46.3) | 56 (41.2) | 62 (45.6) | 65 (47.8) | 0.721 |
OMT, day | 2 (1,2) | 2 (1,2) | 2 (1,3) | 2 (1,2) | 2 (1,2) | 0.417 |
Antibiotic use, % | 115 (21.1) | 23 (16.9) | 32 (23.5) | 24 (17.6) | 36 (26.5) | 0.155 |
Laboratory data | ||||||
Leukocyte number, 10^9 | 8.4 ± 4.1 | 8.2 ± 2.7 | 8.2 ± 3.0 | 8.4 ± 2.6 | 8.8 ± 6.6 | 0.562 |
TC, mmol/L | 4.5 ± 1.0 | 4.3 ± 1.0 | 4.5 ± 1.1 | 4.5 ± 1.0 | 4.4 ± 1.0 | 0.313 |
TG, mmol/L | 1.8 ± 1.2 | 1.5 ± 0.8 | 1.8 ± 1.3 | 1.9 ± 1.4 | 1.8 ± 1.1 | 0.065 |
HDL, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.5 | 1.1 ± 0.2 | 1.0 ± 0.2 | 1.1 ± 0.3 | 0.103 |
LDL, mmol/L | 2.7 ± 0.8 | 2.8 ± 0.8 | 2.8 ± 0.9 | 2.8 ± 0.8 | 2.7 ± 0.9 | 0.504 |
FBG, mmol/L | 6.0 ± 2.5 | 5.8 ± 2.2 | 5.7 ± 2.3 | 6.3 ± 2.7 | 6.2 ± 2.6 | 0.184 |
Glycated hemoglobin, % | 6.4 ± 1.6 | 6.3 ± 1.4 | 6.3 ± 1.4 | 6.6 ± 1.7 | 6.6 ± 1.7 | 0.082 |
Homocysteine, umol/L | 16.0 ± 8.2 | 14.6 ± 6.0 | 16.9 ± 10.0 | 15.8 ± 7.5 | 16.9 ± 8.7 | 0.076 |